Products for Research Use Only
RegisterLogin

Dabogratinib (GMP)

CAT: 0804-HY-159642GSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-159642GSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Dabogratinib (GMP) is Dabogratinib produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib (GMP) is an orally active, selective inhibitor for FGFR3 with an IC50 of 11 nM. Dabogratinib (GMP) exhibits antitumor efficacy against urothelial cancers and solid tumors[1].
CAS Number
2800223-30-5
UNSPSC
12352005
Target
FGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tyra-300-gmp.html
Smiles
O=S(N(C1)CC1(C2)CN2C(N=C3)=CC=C3C4=NNC5=CC=C(O[C@H](C)C6=C(Cl)C=NC=C6Cl)C=C54)(C)=O
Molecular Formula
C25H24Cl2N6O3S
Molecular Weight
559.47
References & Citations
[1]Hudkins RL, et al., Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia. J Med Chem. 2024 Sep 26;67 (18) :16737-16756.
Shipping Conditions
Room temperature
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported

Chemical Information

Dabogratinib

Dabogratinib is an orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 3 (FGFR3), with potential antineoplastic activity. Upon oral administration, dabogratinib specifically targets and binds to certain FGFR3 activating gene alterations, and specifically the gatekeeper mutants V555L/M. This blocks FGFR3-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR3-overexpressing cells. FGFR3, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR3 expression is associated with poor prognosis. It is overexpressed by certain tumor cell types.

CAS Number2800223-30-5
PubChem CID170647464
IUPAC Name5-[(1R)-1-(3,5-dichloro-4-pyridinyl)ethoxy]-3-[6-(2-methylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridinyl]-1H-indazole
Molecular FormulaC25H24Cl2N6O3S
Molecular Weight559.5
XLogP3.6
Topological Polar Surface Area113
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count6
Heavy Atom Count37
Formal Charge0
Complexity916
SMILES
C[C@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3C4=CN=C(C=C4)N5CC6(C5)CN(C6)S(=O)(=O)C
InChI
InChI=1S/C25H24Cl2N6O3S/c1-15(23-19(26)9-28-10-20(23)27)36-17-4-5-21-18(7-17)24(31-30-21)16-3-6-22(29-8-16)32-11-25(12-32)13-33(14-25)37(2,34)35/h3-10,15H,11-14H2,1-2H3,(H,30,31)/t15-/m1/s1
InChIKey
JOAFWIHZEBKYQK-OAHLLOKOSA-N
Chemical Structure
2D Structure
2D structure of Dabogratinib
CAS: 2800223-30-5
CID: 170647464
Formula: C25H24Cl2N6O3S
MW: 559.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight559.5
XLogP33.6
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count6
Exact Mass558.1007652
Monoisotopic Mass558.1007652
Topological Polar Surface Area113 Ų
Heavy Atom Count37
Formal Charge0
Complexity916
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-159642-01Dabogratinib
HY-10219G-01Rapamycin (GMP)
HY-N0737AG-01Harmine (GMP)
HY-N0083GBetulin (GMP)
HY-15682G-01TTNPB (GMP)
HY-15794GNemorubicin (GMP)
HY-B1505GAcefylline (GMP)
HY-13506G-01M344 (GMP)
HY-107632GGYY4137 (GMP)
HY-10227GBortezomib (GMP)

Alternative Products

CatalogName
BLG-G021-503′-GMP
BLG-G022-502′-GMP
GTR19152844GMPαS
M-NU-144S8Br-GMP
NU-237LMant-GMP
TSW-00965-01LNA-GMP
TN9056-01Cyclic GMP
TN10430-013'-GMP
BLG-G024-25GMP-CP
MBS130444-01Biapenem (GMP)

Popular Products